Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

SRENOL 10.9 7.0 56% 1% Other 11.7 10.9 7% 1% Total royalties 62.8 76.5 -18% 6% Other revenues 4.9 3.5 40% <1% Total Revenues 1,086.1 874.3 24% 100%

Unaudited US GAAP results for the nine months to September 30, 2011

Selected Notes to the Financial Statements

(2)  Analysis of revenues

9 months to September 30, 2011 2010 2011 2011 % % of total $M $M change Revenue Net product sales: SP ADHD VYVANSE 587.9 453.6 30% 19% ADDERALL XR 408.0 271.9 50% 13% INTUNIV 157.6 123.0 28% 5% EQUASYM 15.6 16.3 -4% <1% DAYTRANA - 49.4 n/a n/a 1,169.1 914.2 28% 37% GI LIALDA/MEZAVANT 276.0 209.2 32% 9% PENTASA 186.2 175.9 6% 6% RESOLOR 4.0 - n/a <1% 466.2 385.1 21% 15% General products FOSRENOL 127.0 137.4 -8% 4% XAGRID 69.2 65.4 6% 2% CARBATROL 45.6 63.4 -28% 2% 241.8 266.2 -9% 8% Other product sales 71.7 80.2 -11% 2% Total SP product sales 1,948.8 1,645.7 18% 62% HGT REPLAGAL 354.3 242.0 46% 11% ELAPRASE 340.9 297.4 15% 11% VPRIV 186.9 84.0 123% 6% FIRAZYR 18.1 7.7 135% 1% Total HGT product sales 900.2 631.1 43% 29% RM DERMAGRAFT 52.0 - n/a 2% Total RM product sales 52.0 - n/a 2% Total product sales 2,901.0 2,276.8 27% 93% Royalties: ADDERALL XR 66.6 86.3 -23% 2% 3TC and ZEFFIX 64.1 115.3 -44% 2% FOSRENOL 31.4 18.0 74% 1% Other 37.7 34.9 8% 1% Total royalties 199.8 254.5 -21% 6% Other revenues 20.4 8.6 137% 1% Total Revenues 3,121.2 2,539.9 23% 100%

Unaudited results for the three months to September 30, 2011

Non GAAP reconciliation

US GAAP Adjustments Non GAAP Acquisitions Divestments, Amortization & reorganizations Sept & asset integration & discontinued Reclas September 3 months to, 30, impair activities operations -sify 30, 2011 -ments depreciation 2011 (a) (b) (c) (d) $M $M $M $M $M $M Total revenues 1,086.1 - - - - 1,086.1 Costs and expenses: Cost of product sales 166.5 - (9.0) (3.4) (8.6) 145.5 Research and development 201.5 (16.0) - - (5.6)
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Health Enhancement Products, Inc. ... investigating early-stage algae bioactive compounds and metabolic processes, is pleased ... company,s board of directors. Ms. Nola E. Masterson , ... advisor joined the board effective September 17, 2014. ... agree to join our board," states Andrew Dahl , ...
(Date:9/18/2014)... 2014 On Tuesday, Secretary of Energy ... Risch for National Lab Day on the Hill. The ... national laboratory system. Durbin and Risch also formally launched ... awareness of the reach of the national labs as ... address some of our nation's most pressing challenges. , ...
(Date:9/18/2014)... -- Research and Markets has announced the ... 2014" report to their offering. ... professional and in-depth study on the current state of ... provides a basic overview of the industry including definitions, ... market analysis is provided for the international markets including ...
(Date:9/18/2014)... 2014  U.S. biotech company Kultevat has ... for technology developed by the Donald Danforth Plant ... including for applications in production of natural rubber in ... was developed under the direction of Roger Beachy ... president of the Danforth Plant Science Center, and is ...
Breaking Biology Technology:Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Kultevat obtains license of gene switch technology 2
... magnetic fields and tiny iron-bearing particles to drive healthy ... done in animals, may lead to a new method ... diseased organs in people. , The study team, led ... Chair of Pediatric Cardiology at The Childrens Hospital of ...
... BALTIMORE, Jan. 7 Physicians and ... California will benefit from,a new partnership ... University,Medical Center, providing resources to help ... thereby improving patient care., (Logo: ...
... 7 Cephalon, Inc. (Nasdaq:,CEPH) announced today that the ... the JPMorgan Healthcare Conference are now available on the,"Investor ... On Tuesday, January 8, 2008, Frank Baldino, Jr.,Ph.D., Chairman ... the,Conference beginning at 2:00 p.m. Pacific Time (5 p.m. ...
Cached Biology Technology:Researchers use magnetism to target cells to animal arteries 2Researchers use magnetism to target cells to animal arteries 3Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California 2Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available 2
(Date:9/18/2014)... deep in the primitive brainstem has revealed how we ... School of Medicine and the University at Buffalo School ... second "sleep node" identified in the mammalian brain whose ... produce deep sleep. , Published online in August in ... half of all of the brain,s sleep-promoting activity originates ...
(Date:9/18/2014)... research into the Crimean-Congo hemorrhagic fever virus (CCHFV), a ... humans similar to that caused by Ebolavirus, has identified ... has the potential to lead to novel targets for ... research, reported in a paper published today in the ... at the Texas Biomedical Research Institute and their colleagues, ...
(Date:9/18/2014)... and the Quebec government have discovered microplastics (in ... of Fisheries and Aquatic Sciences . , The ... industrial cleansers, to which they are commonly added ... buoyancy, they may readily pass through sewage treatment ... the world,s oceans, but have only recently been ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Research milestone in CCHF virus could help identify new treatments 2Microplastic pollution discovered in St. Lawrence River sediments 2
... have fish-like sensations, advanced ship design and more, four ... on Dec. 23 learned they will receive the nation,s ... researchers have been selected for Presidential Early Career Awards ... at a ceremony at the White House early this ...
... forces in a quest to correct a faulty chromosome through ... , used stem cells to correct a defective "ring chromosome" ... correct chromosome abnormalities that give rise to birth defects, mental ... may be possible to use this approach to take cells ...
... a key difference in the biological mechanisms by which the ... study, published in the journal Nature Immunology and ... Life Sciences, centred on STAT1, a protein that can bind ... in the body. STAT-1 responds to interferon signals, hormone-like ...
Cached Biology News:White House lauds ONR-funded researchers for early success 2Nature study discovers chromosome therapy to correct a severe chromosome defect 2Nature study discovers chromosome therapy to correct a severe chromosome defect 3Research uncovers key difference between our bodies' fight against viruses and bacteria 2
Mouse monoclonal antibody raised against a partial recombinant FBXO11. NCBI Entrez Gene ID = FBXO11...
Mouse polyclonal antibody raised against a partial recombinant LASS3. NCBI Entrez Gene ID = 204219...
... Antibody against Nonmuscle Myosin II Heavy ... (Stored in TBS + 0.03% Thimerosal) ... peptide SDVNETQPPQSE corresponding to the C-terminus ... B (MHC-B) This antibody is effective ...
... Anti-Mi-2 Immunogen : ... acid residues 474-970 of human ... 7.4, 0.105M NaCl, 0.035% sodium ... Assurance: routinely evaluated by immunoblot ...
Biology Products: